Compare Dow Inc (DOW) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Inc vs Inovio Pharmaceuticals Inc — how do they compare? Dow Inc trades at $29.8 (market cap $21.85B), while Inovio Pharmaceuticals Inc trades at $1.17 (market cap $95.85M). The key difference: Dow Inc is far larger — about 228× Inovio Pharmaceuticals Inc's market cap, and Dow Inc pays a 4.62% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| DOW | INO | |
|---|---|---|
Market Cap | $21.85B | $95.85M |
Sector | Basic Materials | Health |
52-Week High | $41.87 | $2.87 |
52-Week Low | $20.65 | $1.05 |
Enterprise Value | $37.62B | $66.86M |
Dividend Yield | 4.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOW trades at $30.37, up 4.62% on the day, with a bullish technical signal from moving averages despite negative profitability metrics. The company reported a net loss of $2.62 billion for 2025, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights Dow's inclusion in discussions about materials stocks benefiting from oil price spikes, while cash flow trends show improved net cash generation in 2025.
The outlook is mixed: analyst consensus suggests 19% upside to the $36.11 price target, but high P/E of 75.93 and negative margins pose valuation risks. Key opportunities include dividend payments and earnings beats, while risks involve sustained profitability challenges and rising debt-to-asset ratios nearing 30%.
INO trades at $1.16, down 1.69% on the day, with a bearish technical outlook from moving averages. The company shows minimal revenue of $65.34K in 2025 and a net loss of $84.95M, resulting in a negative net margin of 130,000%. Recent news highlights an ongoing FDA review for INO-3107 with a PDUFA date of October 30, 2026, alongside shareholder litigation concerns.
The investment case hinges on the binary FDA decision for INO-3107, offering high upside potential but significant risk. Analyst consensus is moderately positive with 53% buy ratings, yet fundamental weaknesses and negative cash flows pose substantial risks for stockholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dow Inc
Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.
Read more on DOW →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
